Jefferies analyst David Windley lowered the firm’s price target on West Pharmaceutical (WST) to $295 from $365 and keeps a Buy rating on the shares. Injectable packaging Contract Manufacturing Organizations face headwinds from vaccines and shifts to oral and multi-dose GLP-1 formats, though the firm thinks oral GLP-1 risk is “largely priced in,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- WST Earnings this Week: How Will it Perform?
- West Pharmaceutical price target lowered to $320 from $390 at Evercore ISI
- West Pharmaceutical Services: GLP-1 Dependency, Emerging Oral-Formulation Risks, and Insufficient Diversification Justify Hold Rating
- West Pharmaceutical: SmartDose Divestiture Clarifies Strategy and Enhances Margin Outlook, Supporting Buy Rating
- West Pharmaceutical to sell SmartDose 3.5mL rights to AbbVie for $112.5M